{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/61a635a4106ee100125850bb/696e51dd36ab0b5268aa43ff?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Future of Clinical Trials in Ireland","description":"<p>Clinical trial activity is not yet fully integrated into the Irish healthcare system as a standard of care, leading to slower patient access to innovative treatments and missed opportunities for system-wide improvement.&nbsp;</p><p><br></p><p>This episode explores the critical need for a research-active health system, the power of incorporating mandatory performance metrics, and the significant financial and clinical value that trials bring to the country. The discussion delves into the work of the National Clinical Trials Oversight Group and Cancer Trials Ireland's ambitious strategy to double the number of open trials.</p><p><br></p><p>Joining Dr. Ciara Kelly is Professor Donal Brennan, a Professor of Gynaecological Oncology at UCD and formerly the Chair of the National Clinical Trials Oversight Group, and Angela Clayton-Lea, the CEO of Cancer Trials Ireland.</p><p><br></p><p>THINGS WE SPOKE ABOUT</p><p><br></p><p>Professor Donal Brennan's career path.</p><p>Trials should be part of standard care.</p><p>The National Clinical Trials Oversight Group.</p><p>The importance of mandatory metrics/KPIs.</p><p>Future outlook for clinical trials in Ireland.</p><p><br></p><p>MORE INFORMATION</p><p><br></p><p>https://www.cancertrials.ie</p><p><br></p>","author_name":"Cancer Trials Ireland"}